Small intestinal neuroendocrine tumours

What changed: Small intestinal neuroendocrine tumours

Cancer page →

Every dated change on the records linked to Small intestinal neuroendocrine tumours, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result6Milestone10This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordSmall intestinal neuroendocrine tumours
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 2

2024 · 2

2018 · 1

2018MilestoneLutetium-177 dotatate
Lutathera approved in the United States and Europe
A milestone in how this cancer is treated.

2017 · 2

2016 · 1

2016MilestoneRADIANT-3 and RADIANT-4
RADIANT-4 extends everolimus to gut and lung tumours; gallium-68 DOTATATE PET approved
A milestone in how this cancer is treated.

2014 · 2

2011 · 1

2011Trial resultRADIANT-3 and RADIANT-4
RADIANT-3 and RADIANT-4 reported
PFS HR 0.

2009 · 2

1988 · 1

1988MilestoneSomatostatin analogues (octreotide, lanreotide)
Octreotide approved for carcinoid syndrome symptoms
A milestone in how this cancer is treated.

1954 · 1

1954MilestoneCarcinoid syndrome and carcinoid heart disease
Carcinoid syndrome described
A milestone in how this cancer is treated.

1907 · 1

1907MilestoneSmall intestinal neuroendocrine tumours
Oberndorfer names the small bowel tumours 'Karzinoid'
A milestone in how this cancer is treated.